• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

    9/4/24 8:00:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email

    Succeeds Dr. Stephen Schwartz Following 14-Year Tenure

    BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition. 

    Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. Previously, he served as CEO and President of PHC Holdings Corporation (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company focused on precision healthcare, growing global revenues and leading its IPO from owners KKR & Co. He also held a variety of senior executive roles in leading life sciences companies, including at Danaher Corporation, Envista Holdings Corporation, and Cardinal Health, Inc., where he demonstrated consistent achievement in organic revenue growth, operational efficiencies, and significant value-creating transactions. Mr. Marotta began his career in sales leadership roles for therapeutics and medical device offerings.

    Frank E. Casal, Chairman of the Azenta Board said, "Following a rigorous search process, aided by a leading executive search firm, the Board and I are thrilled to welcome John as our next President and CEO. We are confident he is the ideal person to lead Azenta into our next chapter. John brings extensive experience leading complex high-growth life sciences businesses around the globe. We look forward to working with him to amplify Azenta's momentum and deliver sustainable value for shareholders."

    Mr. Marotta said, "I am excited to join Azenta and get to know its talented teams worldwide. I have been impressed by Azenta's evolution and am confident that, together, we will expand on its strong foundation to further enhance its offerings while driving growth and profitability. I look forward to hitting the ground running and executing on our tremendous opportunities ahead."

    Mr. Casal continued, "The Board and I extend our deepest gratitude to Steve for his leadership over the last 14 years. Steve joined as President of Brooks Automation in April 2010 and was appointed CEO in August 2010. He led the creation of Azenta as a business division of Brooks into the standalone, pure-play life-sciences leader that it is today, and oversaw the sale of the Semiconductor Solutions Group. Steve leaves a profound impression on all stakeholders, having led our team to create significant value for shareholders during his tenure and enable customers to realize impactful breakthroughs. We thank Steve and wish him all the best."

    Dr. Schwartz added, "It has been a privilege to be a part of this amazing Azenta team on a journey to become an established life-sciences company that we believe uniquely enables customers around the globe in their pursuit of scientific progress. I am confident in Azenta's future success as it moves into this next chapter and I look forward to working with John through the transition."

    About Azenta Life Sciences

    Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.

    Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.

    "Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934

    Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Forward-looking statements include but are not limited to statements about the transition to John P. Marotta as Azenta's President and CEO and ability to deliver shareholder value. Factors that could cause results to differ from our expectations include the following: our ability to ensure a smooth CEO transition; our ability to reduce costs effectively; the volatility of the life sciences markets the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; price competition; disputes concerning intellectual property; uncertainties in global political and economic conditions; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.

    AZENTA INVESTOR CONTACTS:

    Yvonne Perron

    Vice President, Financial Planning & Analysis and Investor Relations

    [email protected]

    Sherry Dinsmore

    [email protected] 

    AZENTA MEDIA CONTACT:

    Emily Claffey

    FGS Global

    [email protected] 

    Azenta logo (PRNewsfoto/Azenta)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-announces-appointment-of-john-p-marotta-as-ceo-302237689.html

    SOURCE Azenta

    Get the next $AZTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZTA

    DatePrice TargetRatingAnalyst
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    4/4/2024$64.00Hold
    Jefferies
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    7/19/2023Mkt Perform
    Raymond James
    5/10/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    2/9/2023$65.00 → $60.00Overweight → Equal-Weight
    Stephens
    1/3/2023$60.00 → $62.00Outperform → In-line
    Evercore ISI
    3/31/2022$106.00Buy
    B. Riley Securities
    More analyst ratings

    $AZTA
    SEC Filings

    See more
    • Azenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Azenta, Inc. (0000933974) (Filer)

      5/7/25 7:05:31 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Azenta, Inc. (0000933974) (Filer)

      4/9/25 4:30:57 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • SEC Form 10-Q filed by Azenta Inc.

      10-Q - Azenta, Inc. (0000933974) (Filer)

      2/10/25 5:19:29 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Azenta Inc.

      SC 13G/A - Azenta, Inc. (0000933974) (Subject)

      11/13/24 4:05:02 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Amendment: SEC Form SC 13D/A filed by Azenta Inc.

      SC 13D/A - Azenta, Inc. (0000933974) (Subject)

      11/4/24 8:41:47 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • SEC Form SC 13G filed by Azenta Inc.

      SC 13G - Azenta, Inc. (0000933974) (Subject)

      10/31/24 11:55:02 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO and Treasurer Lin Lawrence Y. was granted 2,200 units of Common, increasing direct ownership by 6% to 37,513 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/13/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Koffey Quentin was granted 4,040 shares, increasing direct ownership by 406% to 5,035 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/11/25 4:48:51 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Malus Alan J was granted 4,040 units of Common, increasing direct ownership by 406% to 5,035 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/11/25 4:10:12 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Publishes its 2024 Environmental, Social, & Governance (ESG) Report

      BURLINGTON, Mass., March 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2024. The report offers a comprehensive look at the Company's ESG approach and showcases accomplishments in three main pillars: Environmental Protection: We understand the broad impact of our operations and the potential to impact the world. We are committed to evaluating ways to reduce our environmental footprint while continu

      3/24/25 4:05:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Azenta upgraded by Stephens with a new price target

      Stephens upgraded Azenta from Equal-Weight to Overweight and set a new price target of $60.00 from $50.00 previously

      12/18/24 7:25:24 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Jefferies initiated coverage on Azenta with a new price target

      Jefferies initiated coverage of Azenta with a rating of Hold and set a new price target of $64.00

      4/4/24 7:29:19 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • B. Riley Securities reiterated coverage on Azenta with a new price target

      B. Riley Securities reiterated coverage of Azenta with a rating of Buy and set a new price target of $79.00 from $61.00 previously

      2/1/24 8:17:35 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Financials

    Live finance-specific insights

    See more
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024

      BURLINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the fourth fiscal quarter of 2024 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 148 $ 151 $ 142 (2) % 4 % Organic growth 4 % Sample Management Solutions $ 81 $ 85 $ 79 (4) % 3 % Multiomics $ 66 $ 66 $ 63 0 % 6 % Diluted EPS Continui

      2/5/25 7:00:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

      NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

      11/19/24 5:56:00 PM ET
      $AZTA
      $CON
      $ENV
      $FLEX
      Industrial Machinery/Components
      Technology
      Medical Specialities
      Health Care
    • Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

      William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i

      11/4/24 8:00:00 AM ET
      $AZTA
      $BV
      $LVWR
      Industrial Machinery/Components
      Technology
      Business Services
      Consumer Discretionary
    • AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

      Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P

      9/4/24 8:00:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and General Manager, Genom Zhou Ginger bought $19,132 worth of Common (417 units at $45.88), increasing direct ownership by 2% to 27,916 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/4/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • President and CEO Marotta John was granted 83,622 units of Common and bought $552,904 worth of Common (13,967 units at $39.59), increasing direct ownership by 2,982% to 100,862 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:16 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Cornog William L bought $495,000 worth of Common (12,500 units at $39.60) (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:11 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology